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Abstract Mast cells can serve as a possible important source of 
cytokine production in inflamed tissue which can be regulated by 
stimuli different from those activating other immune system cells. 
To study the expression of specific genes in mast cells derived 
from small human colonic mucosal endoscopic biopsies, we first 
modified a previously reported procedure to achieve a signifi-
cantly enriched mast cell fraction. Then, by using single-cell RT-
PCR analysis the expression of the IgE Fc receptor (FceRI) and 
c-kit mRNA was determined. It was observed that the FceRI-
positive cells also expressed c-kit. This observation provided 
further evidence that FceRI-positive cells are indeed mast cells. 
Analysis of biopsies from 12 patients (four control and eight 
patients with inflammatory bowel disease (IBD)) was carried out, 
revealing that all of the FceRI-positive cells expressed IL-3, 
while the expression of IL-4 was detected only in some of these 
positive cells. TNFa was not detected in these cells. Therefore, it 
would seem that most intestinal mast cells produce IL-3. Since it 
has been reported that IL-3 synthesis was down-regulated in 
steroid-treated cells, the expression pattern of IL-3 in intestinal 
mast cells derived from steroid-treated IBD patients was then 
determined. IL-3 mRNA was detected in only two out of 24 
FceRI-positive cells derived from these steroid-treated patients. 
These results lend strong support to the idea that the down-
regulation of IL-3 in mast cells derived from steroid-treated IBD 
patients occurs in vivo and could be an important mechanism for 
immunomodulation in IBD. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The gastrointestinal (GI) immune system is being constantly 
exposed to massive antigenic stimuli and this interaction ini-
tiates humoral and cellular responses. Since cytokines were 
implicated in having a vital influence on the regulation, matu-
ration, activation, proliferation and specific functions of the 
immune cells, they may also operate in the regulation of the 
immune responses in the GI tract [1-3]. However, essential 
information regarding their role in the immuno-regulation 
and inflammation of the human gut is limited. Furthermore, 
different stimuli induce the production of cytokines in differ-
ent immune cells. For example, different enhancers are used 
for IL-4 expression in mast cells and in T-cells [4]. Therefore, 
one cannot readily deduce from the regulation of a gene in the 
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one cell type that it is regulated similarly in other cell types. 
A possible important site of cytokine production in in-
flamed tissue are mast cells, in which cytokine production is 
regulated by different stimuli than in T-cells. Mast cells which 
are characterized by their high-affinity Fc receptor (FceRI), 
have been postulated to operate in concert with other cells in 
immune and inflammatory responses in the gut [5-7]. These 
cells are capable of synthesizing and releasing histamine, cy-
tokines, lipid-derived compounds, proteases, endothelines 
growth and angiogenic factors [3,7-12]. 
IL-3 plays a major role in the differentiation and growth 
regulation of a variety of hematopoietic cell types including 
basophils and mast cells [3]. Recently, it was reported that 
cyclosporine, a potent drug for the treatment of refractory 
cases of inflammatory bowel disease (IBD), significantly de-
creases the half-life of IL-3 mRNA in vitro [13]. Furthermore, 
glucocorticoids, which are widely used for treatment of IBD, 
were shown to significantly reduce the levels of IL-3 in T-cells 
from asthmatic patients [14]. Since mast cells might produce a 
significant amount of IL-3, the possible down-regulation of 
this cytokine production might be an important common tar-
get of immunomodulatory drugs in IBD. We therefore deter-
mined the expression of cytokine in mast cells from normal, 
inflamed and steroid-treated intestinal tissue. TNFa was 
studied in relation to IBD as a pro-inflammatory factor 
[2,4,5]. IL-3 functions as a differentiating factor for immature 
T-lymphocytes and also promotes and maintains basophilic 
and mast cell growth in vitro [3]. IL-4 has a major role in 
the control of allergic inflammation, since not only can it 
synergize with other cutokines to cause increased proliferation 
of mast cells, it is also essential for the isotope switching in B-
cells from IgG to IgE [11]. Expression of this cytokine has 
been reported in human basophils, bone marrow-derived mast 
cells and in lung mast cells from allergic patients [15,16]. 
IL-8 is a member of the chemokine family of cytokines, 
which are small proteins with several important roles in the 
inflammatory response [17]. It is produced by a variety of cell 
types and was recently shown to be produced in the human 
mast cell line, HMC-1, and in skin mast cells [18]. 
In the current work we present an approach for studying 
cytokine production by human colonic FceRI-positive cells. 
These cells, which were derived from endoscopic mucosal bi-
opsies, were examined for cytokine mRNA accumulation by 
using the single-cell polymerase chain reaction. 
Previously, we have used the single-cell RT-PCR approach 
to analyse semiquantitavely the expression of various genes in 
mast cells [19] and in FceRI-positive cells derived from human 
endoscopic mucosal biopsies [20]. Here, we utilized the same 
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approach to obtain semiquantitative data regarding the ex-
pression of IL-3, IL-4 and IL-8 in FceRI-positive cells derived 
from biopsies of IBD patients. 
2. Materials and methods 
2.1. Isolation and enrichment of human colonic mast cells 
Mucosal specimens (weight 15-25 mg/sample) were obtained during 
colonoscopy performed for diagnosis and disease follow-up. Speci-
mens were taken from normal mucosa as well as mucosa from IBD 
patients who had either been treated with glucocorticoids (steroids) or 
had not received any steroid treatment. The study was approved by 
the local hospital Helsinki committee. The samples were incubated in 
saline overnight at 4°C prior to the digestion procedure. After clean-
ing the mucus, the tissue was incubated in RPMI-1640 medium sup-
plemented with 25 mM HEPES and 1 mM dithiothreitol [21]. Then, in 
order to separate the cells from the tissue, the tissue was sequentially 
treated with 30 U of collagenase (Sigma, Israel) at 37°C for 45 min 
and the cell suspension was filtered through a nylon wool column. The 
percentage of the mast cells was determined in the cell eluate by 
toluidine blue staining. In order to separate single cells, serial dilution 
of the cells was performed in a Terasaki microtiter plate until single 
cells were visualized in each well by inverted microscope. Each single 
cell was suspended in 10 |il of HBSS medium supplemented with 25 
mM HEPES and incubated for 6 h in 5% C0 2 at 37°C. 
2.2. Preparation of RNA 
Each cell was transferred from its well into a 1.5-ml Eppendorf tube 
containing 100 ul of lysis buffer (10 mM Tris-HCl, pH 8.0, 100 mM 
NaCl, 1 mM EDTA and 0.5% SDS) supplemented with 100 ug pro-
teinase K and incubated for 10 min at 37°C. This was followed by the 
addition of 18 ul of 3 M NaCl and 50 ug oligo-dT cellulose. The 
mixture was incubated overnight by rotation at room temperature. 
The oligo-dT cellulose was washed 3 times with binding buffer (0.5 
M NaCl, 10 mM Tris-HCl, pH 8.0, 1 mM EDTA and 0.1% SDS) 
followed by one wash with washing buffer (0.1 M NaCl, 10 mM Tris-
HCl, pH 8.0, 1 mM EDTA and 0.1% SDS). The RNA was eluted by 
incubating the oligo-dT for 10 min at room temperature with 50 ul of 
10 mM Tris-HCl, pH 8.3. The mRNA was ethanol-precipitated in the 
presence of 5 ug tRNA, spun and then washed with 70% ethanol. The 
dried RNA pellet was redissolved in RT buffer containing RNase 
inhibitor [19,20]. 
2.3. Oligonucleotide probes and primers 
cDNA probes for human aFceRI (kindly provided by Dr. J.P Ki-
net, National Institutes of Health, Bethesda, MD), human IL-3 
(kindly provided by the Genetic Institute, Cambridge, MA), human 
IL-4 (provided by DNAX, Palo Alto, CA), human IL-8 (kindly pro-
vided by Dr. Matsushuma, National Cancer Institute, Frederic, MD), 
human c-kit (kindly provided by A. Bernstein, Toronto, Canada) and 
for human TNFce the PCR amplified fragment from RNA derived 
from human peripheral blood leukocytes was used as a probe. The 
sequence targeted by each pair of oligonucleotides was designed to 
span an intron/exon border in order that fragments amplified from 
cDNA generated from mRNA could be readily distinguished by their 
much smaller size from those predicted to be generated from any 
contaminating genomic DNA. aFceRI oligonucleotide primers: 
sense: 5'-ATG GCT CCT GCC ATG GAA TCC CCT ACT-3' and 
anti-sense: 5'-GGT TCC ACT GTC TTC AAC TGT GGC AAT-3' 
corresponding to bases 106-519 [22]. IL-4 primers: sense: 5'-ATG 
GGT CTC ACC TCC CAA CTG CTT CCC-3' and anti-sense: 5'-
ATT TCT CTC TCA TGA TCG TCT TTA GCC-3' corresponding 
to bases 64-505 [23]. IL-3 primers: sense: 5'-GCT CCC ATG ACC 
CAG ACA ACG TCC TTG-3' and anti-sense: 5'-GTC CTT GAT 
ATG GAT TGG ATG TCG CGT-3' corresponding to bases 67-
360 [24]. IL-8 primers: sense: 5'-ATG ACT TCC AAG CTG GCC 
GTG GCT CTC-3' and anti-sense: 5'-ATG AAT TCT CAG CCC 
TCT TCA AAA ACT-3' corresponding to bases 1-295 [25]. TNFa 
primers: sense: 5'-CTG CGC CAG GCA ACG GGT CCT GCG 
CCT-3' and anti-sense: 5'-CAG CTT CAG GTC CCT CAA AGC 
GCT GCG GGG-3' [26]. c-Kit primers: sense: 5'-TCA CAG CTT 
GGC AGC CAG-3' and antisense: 5'-GGG GAT CTG CAT CCC 
AGC AAG-3' corresponding to 2384-2754 [27]. 
2.4. RT-PCR 
RNA was reverse transcribed into cDNA essentially as previously 
described [19,20]. RNA from one single cell was incubated at 37°C for 
60 min with a mixture of 400 U of MMLV-RT and the following 
reagents: 3 uM sequence specific antisense primers of aFceRI and 
either one of the cytokines described above: 1:5 (V/V) X5 reaction 
buffer, 0.5 mM dNTP and 5U of RNAsin in 20 ul of final volume. 
Each of the RT mixtures was added to 2.5 U of taq 1 DNA polymer-
ase to a final volume of 100 ul containing 3 uM 5' sequence-specific 
primer of aFceRI and either one of the cytokines described above: 
0.25 mM dNTP, 10 mM Tris-HCl, pH 8, 1.5 mM MgCl2, 50 mM KC1 
and 0.1% (w/v) gelatin. The mixture was covered with mineral oil and 
subjected to the amplification process in a repeated three temperature 
cycle in a programmable thermal controller (MJ Research Inc.). The 
temperature used in the annealing cycle was determined according to 
the G-C content of the primers. The samples were amplified up to 30 
cycles. 
2.5. Agarose gel electrophoresis 
The PCR mixture (10 ul) was added to 2 ul of loading dye elec-
rophoresed in a 80-V constant voltage field in 1% sodium agarose 
until the bromophenol-blue dye front had migrated 8 cm. 
2.6. Southern blot hybridization analysis 
The PCR-amplified fragments separated on agarose gels were trans-
ferred to nylon hybridization transfer membranes. The membrane-
bound DNA was denatured with 0.5 N NaOH. Each of the hybrid-
ization transfer membranes was hybridized with a 32P-labelled probe 
by standard techniques and washed at 65°C for 20 min in 0.1 XSSC 
containing 0.1% SDS prior to autoradiography. 
3. Results 
3.1. Isolation and enrichment of colonic mucosal mast cells 
Using the procedure for isolation of intestinal mast cells 
[21], only 2% of the cells were found to be positively stained 
by toluidine blue. Therefore, this procedure was modified by 
the addition of overnight pre-incubation of the tissue at 4°C 
prior to the enzymatic digestion. This modification has been 
described previously for the purification of viable and well-
functioning human lung mast cells [28]. By using this modifi-
cation, 20-35% of the column-eluted cells were positively 
stained with toluidine blue. 
3.2. Cytokine expression by FceRI-positive cells 
In order to determine a few of the cytokines expressed by 
500 bp 
500 bp 
Fig. 1. Expression of c-kit in FceRI-positive cells isolated from bi-
opsies of human colonic mucosa. mRNA from single cells was re-
verse-transcribed with aFceRI and c-kit primers and the products 
were PCR amplified for 30 cycles. PCR products were separated by 
agarose gel electrophoresis, transferred to nylon hybridization mem-
brane, and then hybridized with 32P-labeled cDNAs for aFceRI. 
Only those cell-derived products that were found to be FceRI-posi-
tive after autography were separated again by agarose gel electro-
phoresis, transferred to nylon hybridization membrane, and then hy-
bridized with 32P-labeled cDNA for c-kit and autoradiographed for 
17 h. One representative experiment out of three is shown. 
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individual colonic mucosal FceRI-positive cells, we applied 
the RT-PCR single-cell technique previously utilized by us 
and others [19,20,29]. The characterization of the PCR-ampli-
fied cDNA fragments generated by using oligonucleotides spe-
cific for FceRI and either one of the cytokines was performed 
by the hybridization of the Southern blots with the specific 
32P-labelled cDNAs. A good correlation was found between 
the percentage of toluidine blue-positive cells and those ex-
pressing FceRI gene. Furthermore, in order to strengthen the 
possibility that the majority of the FceRI-positive cells are 
mast cells rather then basophils, eosinophils or monocytes 
three types of cells which also express surface FceRI [30-32] 
we determined whether the FceRI-positive cells also expressed 
c-kit as this proto-oncogene is known to be expressed in mast 
cells but not in basophils, eosinophils or monocytes [33]. Fig. 
1 shows that all of the FceRI-positive cells expressed the c-kit 
although there were differences in the levels of c-kit products 
in the various cells. 
It was previously reported that the a-subunit of the FceRI 
is consistently expressed in mast cells [34]. Thus, this tran-
script should be considered a reference for the various cyto-
kine mRNAs amplified in the single cells. Fig. 2 shows a 
representative experiment using the single-cell RT-PCR tech-
nique to detect cytokines expressed by mucosal FceRI-positive 
cells. IL-3 was expressed in all of these cells while IL-8 was 
expressed in two out of four cells. IL-4 was expressed in one 
out of four cells. Although the single-cell RT-PCR method as 
used here cannot determine quantitatively the level of mRNA 
in an individual cell, it allows us to observe, under defined 
PCR cycles, which of the FceRI-positive cells express these 
cytokines above a certain level. 
Expression of IL-3, IL-4 and IL-8 by the FceRI-positive 
cells derived from normal and IBD mucosa is summarized 
a FceRl-
IL-3 
IL-4 
IL-8 
— 5 0 0 bp 
— 3 0 0 bp 
— 5 0 0 bp 
— 300 bp 
— 5 0 0 bp 
— 3 0 0 bp 
— 5 0 0 bp 
— 3 0 0 bp 
Fig. 2. Expression of IL-3, IL-4, IL-8 mRNAs in FceRI-positive 
cells isolated from biopsies of human colonic mucosa. mRNA from 
single cells was reverse-transcribed with ocFceRI primers and primers 
from either one of the following cytokines: IL-3, IL-4 and IL-8. 
The products were PCR amplified for 30 cycles. PCR products were 
first hybridized with 32P-labeled cDNAs for aFceRI. Only those 
cell- derived products that were found to be FceRI-positive after 
autoradiography were separated again by agarose gel electrophore-
sis, transferred to nylon hybridization membrane, and then hybrid-
ized with 32P-labeled cDNAs for aFceRI, IL-3, IL-4 and IL-8 and 
autoradiographed for 17 h. One representative experiment out of 
four is shown. 
aFceRI 
IL-3 
500 bp 
300 bp 
Fig. 3. Inhibition of IL-3 mRNA expression in FceRI-positive cells 
isolated from biopsies of human colonic mucosa derived from ster-
oid-treated patients. mRNA from single cells was reverse-transcribed 
with aFceRI and IL-3 primers. The products were PCR amplified 
for 30 cycles. PCR products were first hybridized with 32P-labeled 
cDNAs for aFceRI. Only those cell-derived products that were 
found to be FceRI-positive after autoradiography were separated 
again by agarose gel electrophoresis, transferred to nylon hybridiza-
tion membrane, and then hybridized with 32P-labeled cDNAs for 
IL-3 and autoradiographed for 17 h. One representative experiment 
out of five is shown. 
in Table 1. All single cells examined are FceRI-positive, c-
kit-positive and predicted to be toluidine blue-positive. All 
IBD cases had active ulcerative colitis, and biopsies were tak-
en from the inflamed mucosa. There was no significant differ-
ence in the recovery of toluidine blue-positive cells isolated 
from biopsies taken from IBD or control subjects. IL-3 was 
expressed in all FceRI-positive cells. Interestingly, IL-8 was 
significantly much less expressed in FceRI-positive cells de-
rived from inflammatory than from normal mucosa (16% vs. 
85% respectively; Table 1). Cells from the inflamed mucosa 
were more likely to express IL-4 as compared to FceRI-pos-
itive cells derived from normal mucosa (38% vs. 13% in con-
trol). In repeated experiments, utilizing oligomers with which 
successful amplification of TNFa from peripheral blood cell 
mRNA has been carried out, we could not detect any TNFa 
from FceRI-positive cells derived from either inflammatory or 
normal mucosa (results not shown). 
3.3. Effect of steroid-treatment on IL-3 expression in mast cells 
Since a large number of IBD patients are treated with ster-
oids, the accumulation of IL-3 mRNA was determined in 
FceRI-c-kit-positive cells isolated from human colonic muco-
sa of 10 steroid-treated IBD patients. There was no significant 
difference in the toluidine blue-positive cells isolated from 
biopsies taken from IBD, control or steroid-treated IBD sub-
jects. In stark contrast to the 44 IL-3-positive cells isolated 
from untreated mucosal FceRI-positive cells, only 4 IL-3 pos-
itive cells were detected out of 40 FceRI-positive cells isolated 
from steroid-treated IBD patients (Table 1 and Fig. 3). 
4. Discussion 
Mast cells have been shown to play an important role in 
physiological processes as well as in inflammation and im-
mune response [8,11,35]. They are a rich source of various 
biologically active mediators such as histamine, eicosanoids, 
platelet activating factor, cytokines, growth factors and endo-
thelins [7,9-12] which act in the local milieu as regulators and 
paracrine effectors. They have also been reported to operate in 
immune and inflammatory responses involving the GI tract 
[2,3,5-7,35-37]. However, most of the data regarding the role 
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Table 1 
Cytokine production by intestinal mucosal FceRI-positive cells 
Sample 
Control 
1 
2 
3 
4 
Total 
Inflamed tissue 
1 
2 
3 
4 
5 
6 
7 
8 
Total 
Steroid-treated IBD patients 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Total 
FceRI/total cells 
1/ 10 
11 20 
5/ 10 
2/ 10 
15/ 50 
4/ 10 
5/ 10 
3/ 10 
1/ 10 
5/ 10 
3/ 10 
5/ 10 
3/ 10 
29/ 80 
10/ 30 
5/ 10 
2/ 10 
4/ 10 
3/ 10 
3/ 10 
4/ 10 
4/ 10 
2/ 10 
3/ 10 
40/120 
IL-3/FceRI 
1/ 1 
11 1 
5/ 5 
2/ 2 
15/15 
4/ 4 
5/ 5 
3/ 3 
1/ 1 
5/ 5 
3/ 3 
5/ 5 
3/ 3 
29/29 
0/10 
2/ 5 
0/ 2 
0/ 4 
0/ 3 
0/ 3 
1/ 4 
0/ 4 
0/ 2 
1/ 3 
4/40 
IL-4/FceRI 
1/ 1 
0/ 7 
1/ 5 
0/ 2 
2/15 
0/ 4 
1/ 5 
1/ 3 
0/ 1 
5/ 5 
1/ 3 
— 
-
8/21 
— 
-
— 
-
— 
-
— 
-
— 
-
-
IL-8/FceRI 
0/ 1 
11 1 
4/ 5 
— 
11/13 
0/ 4 
0/ 5 
3/ 3 
0/ 1 
0/ 5 
— 
— 
— 
3/18* 
— 
— 
— 
— 
— 
— 
— 
— 
— 
— 
-
Statistical evaluation was performed according to the 2-tailed Fisher exact test ('significantly different from control P< 0.001). 
of mast cells in the GI tract have been derived from animal 
studies [7]. Reports on the characterization and function of 
human intestinal mast cells are limited [15,21,36]. The main 
obstacle for studying mast cells derived from a specific organ 
is in obtaining a pure population of these cells. Fox and her 
colleagues achieved a fraction of only 6% of human colonic 
mucosal mast cells from isolated surgical specimens [21], and 
Befus and his colleagues reported on 8% mast cell purity 
derived from human gut [37]. Therefore, studies utilizing 
pure and viable human mast cells directly isolated from the 
human intestine have not yet been carried out. We decided to 
address the issue of studying pure human intestinal mast cells 
by a two-step approach. First, we enriched the fraction of 
human colonic mast cells obtained from small endoscopic 
mucosal biopsies up to 35% by modifying the previously re-
ported procedure [21]. Then, by using the single-cell RT-PCR 
technique [19,20] only those cells which expressed FceRI were 
further analyzed for their specific cytokine content. The pos-
itive correlation between the percentage of the toluidine-pos-
itive and cells expressing FceRI, and the observation that all 
of the FceRI-positive cells expressed c-kit, supported the as-
sumption that the majority of the isolated FceRI-positive cells 
were mast cells. Thus, the reported technique provides a reli-
able and reproducible tool for close study of the FceRI-pos-
itive cells, probably mast cells, isolated from mucosal speci-
mens obtained during GI endoscopic procedures. 
Single-cell RT-PCR has been used for the characterization 
of cells which are widely dispersed between other cell types. 
For example, the expression pattern of several genes was de-
termined by this method in a number of Reed-Stenberg cells 
from several patients [29]. A possible advantage of this meth-
od compared with in situ hybridization is the ability to detect 
the expression of several genes in a single defined cell. 
Although this method is not quantitative, by performing a 
limited number of PCR cycles and detection of expression 
of the same genes in a number of cells, semiquantitative in-
formation can be obtained if there are large differences in gene 
expression patterns in different situations. Previously we uti-
lized this method to demonstrate the induction of IL-3 pro-
duction in mast cell in vitro by co-culturing them with fibro-
blasts [19]. Therefore, the results from our study can provide 
general information on the expression of specific genes in in-
testinal FceRI-positive cells. This, of course, could be carried 
out only in extreme cases where there are large differences in 
the expression rate of specific gene. 
Since cytokines have been implicated as essential paracrine 
modulators in experimental colitis and IBD [1-3,38], the ex-
pression of IL-3, IL-4 and IL-8 was determined in the purified 
FceRI-positive cells. Although the total number of IL-4 ex-
pressing cells was higher in FceRI-positive cells from IBD 
patients, most of this increase stemmed from the results ob-
tained from one patient and therefore cannot be considered 
significant. Recently Bradding et al. demonstrated by in situ 
hybridization that IL-4 was preferentially expressed in a sub-
set of human bronchial mucosa mast cells [39]. Further re-
search is needed in order to determine whether IL-4 is pro-
duced in a specific subset of mast cells in intestinal mucosa. 
We also checked the expression of the pro-inflammatory 
cytokine IL-8 in FcERI-positive cells. This cytokine has been 
shown to be expressed by human mast cells [18] and also by 
GI epithelial cells [40]. 
Although IL-8 is a typical feature of mucosal inflammation, 
we observed that IL-8 was expressed less in FceRI-positive 
cells derived from inflamed as opposed to normal mucosa. 
However, this result is based on cells from only a few pa-
tients; therefore, further studies have to be carried out in 
order to elucidate the expression of this cytokine in mucosal 
mast cells derived from inflamed tissues. Since IL-8 is also 
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produced by epithelial cells, a possibility exists that its total 
amount is increased in inflamed tissue as a result of produc-
tion of this cytokine by epethelial cells, while mast cell pro-
duction of IL-8 is reduced. 
We were unable to detect TNFce cDNA from FceRI-pos-
itive cells derived from inflamed or from normal mucosa. 
Although we used the same TNFce primers for the successful 
amplification of cDNA from mRNA of peripheral blood cells, 
our failure could be a technical one. However, in this respect 
it is interesting to note that immunohistochemistry studies of 
intestinal inflamed tissue revealed that this cytokine was most 
probably produced by monocytes [41]. 
IL-3 is one of the predominant cytokines produced by acti-
vated mast cells and has an effect on the differentiation and 
proliferation of several hematopoietic lineages, including 
those leading to the production of mast cells and basophils. 
Interestingly, we found that all mast cells, derived either from 
normal tissue or from patients with active IBD, expressed IL-
3. It seems that intestinal FceRI-positive cells produce a basal 
level of IL-3. A recent study has shown that glucocorticoid 
therapy of asthmatics is associated with a reduction in the 
expression of IL-3 mRNA and in the secretion of the IL-3 
protein in T-cells [14]. Furthermore, cyclosporine, a potent 
drug in the treatment of IBD was shown to reduce mast cell 
IL-3 half-life in vitro. Thus, studying IL-3 expression in mu-
cosal mast cells derived from steroid-treated IBD patients may 
provide an important clue as to whether this immunomodu-
latory mechanism occurs in mast cells in vivo. Our detection 
of only four expressing cells out of 40 FceRI-positive cells 
derived from the mucosa of 10 steroid-treated patients is in 
sharp contrast to the detection of 44 positive IL-3 expressing 
cells out of 44 FceRI-positive cells from untreated patients, 
therefore providing strong evidence in support of the notion 
that IL-3 expression is down-regulated in vivo in FceRI-pos-
itive mucosal cells. Thus, mast cell IL-3 down-regulation may 
be one of the major targets of immunomodulatory treatment 
in IBD patients. 
In summary, these results demonstrate the expression of 
several types of cytokines in intestinal FceRI-positive cells, 
which are mostly mast cells. Furthermore, our demonstration 
of a large reduction in the number of FceRI-positive cells 
expressing IL-3 from intestinal mucosa of steroid-treated pa-
tients, lends strong support to the idea that the down-regula-
tion of IL-3 in mast cells derived from steroid-treated IBD 
patients occurs in vivo and could be an important mechanism 
for immunomodulation in IBD. 
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